Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient ...
LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback